Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 1567 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence

Singh Awadhesh Kumar, Singh Ritu

Year : 2016| Volume: 20| Issue : 2 | Page no: 245-253

   This article has been cited by
1 In vitro and in silico inhibition properties of fucoidan against a-amylase and a-D-glucosidase with relevance to type 2 diabetes mellitus
Lakshmana Senthil S.,Chandrasekaran Raghu,Arjun H.A.,Anantharaman P.
Carbohydrate Polymers. 2019; 209: 350
[Pubmed]  [Google Scholar] [DOI]
2 The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
Annayya R. Aroor,Camila Manrique-Acevedo,Vincent G. DeMarco
Cardiovascular Diabetology. 2018; 17(1)
[Pubmed]  [Google Scholar] [DOI]
3 Curcumin improves diabetes mellitus-associated cerebral infarction by increasing the expression of GLUT1 and GLUT3
Mingyu Xia,Zankai Ye,Yanfeng Shi,Libo Zhou,Yang Hua
Molecular Medicine Reports. 2017;
[Pubmed]  [Google Scholar] [DOI]
4 Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes
André J. Scheen
Clinical Pharmacokinetics. 2016;
[Pubmed]  [Google Scholar] [DOI]
5 Perfil clínico de los pacientes con diabetes mellitus tipo 2 tratados con inhibidores del cotransportador sodio-glucosa tipo 2 y experiencia clínica real en España
Gabriel Cuatrecasas,Fernando Goñi-Goicoechea
Medicina Clínica. 2016; 147: 30
[Pubmed]  [Google Scholar] [DOI]


Read this article